Sponsored
Millions of Medicare beneficiaries gained access to a new low-cost GLP-1 program on July 1, and the timing lines up with a wave of research on whether these same medications could eventually help treat substance use disorders.
For people managing both a weight-related health condition and a history of addiction, the free and low-cost rehab conversation now includes a new piece: how prescription drug coverage is changing.
What the Medicare GLP-1 Bridge Program Covers
The Medicare GLP-1 Bridge Program, run by the Centers for Medicare and Medicaid Services, lets eligible Part D beneficiaries get GLP-1 medications including Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay.
The program runs through December 31, 2027, and marks the first time Medicare has helped pay for a drug prescribed solely for weight management rather than diabetes or another approved condition.
Eligibility depends on body mass index and related health markers. People with a BMI of 35 or higher qualify outright.
Those with a BMI between 27 and 35 may qualify if they also have conditions such as uncontrolled high blood pressure, prediabetes, a prior heart attack or stroke, or chronic kidney disease. A doctor must submit a prior authorization request before coverage begins.
It is important to be clear about what this program does and doesn’t do. The Bridge Program covers GLP-1 medications for weight management, not for treating substance use disorders. Medicare does not currently cover GLP-1s as an addiction treatment.
The Growing Research on GLP-1s and Addiction
Separate from the Medicare coverage change, researchers have spent the past year building evidence that GLP-1 medications may affect more than appetite.
A study published in the BMJ found that people taking GLP-1 drugs were less likely to develop substance use disorders involving alcohol, opioids, nicotine, and other substances compared to people not taking the medications.
Researchers involved in that work have been careful to note that GLP-1s are approved as diabetes and obesity treatments, not addiction treatments, even as the pattern of reduced substance use risk has held up across multiple studies.
The proposed mechanism involves the same brain reward pathways that GLP-1s affect when reducing food cravings.
Some researchers believe this may also help quiet cravings for alcohol or other drugs, though this use remains under study rather than approved by the FDA.
Who Qualifies for Free or Low-Cost Treatment
For people already managing a substance use disorder alongside obesity or another qualifying condition, the $50 monthly Bridge Program cost could mean lower out-of-pocket spending on a medication their doctor may already be considering for other reasons.
This does not replace addiction treatment, but it can reduce one financial barrier for people juggling multiple health conditions on a fixed income.
People without Medicare insurance who are looking for low-cost paths to addiction treatment still have options through Medicaid, sliding-scale clinics, and state-funded programs that do not depend on this new federal pilot.
How to Access These Resources
Ask your prescribing doctor whether you meet the BMI and health criteria for the Bridge Program if you already take or are considering a GLP-1 medication.
Check whether your Medicare Part D plan participates in the Bridge Program before assuming coverage applies.
Contact SAMHSA’s national helpline at 1-800-662-4357 for free, confidential guidance on substance use treatment options regardless of insurance status.
Finding Affordable Treatment
Rehabs.org lists free and low-cost treatment options nationwide, including programs that work with Medicare and Medicaid beneficiaries. Call
800-914-7089
(
Sponsored)
to find affordable care that fits your situation, whether or not it involves navigating new prescription drug programs like this one.
More Articles Like This
